Hbm Holdings Ltd (2142)

Currency in HKD
10.99
+0.59(+5.67%)
Closed·
2142 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Trading near 52-week High
2142 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
10.0510.99
52 wk Range
1.0610.99
Key Statistics
Bid/Ask
10.99 / 10.99
Prev. Close
10.4
Open
10.45
Day's Range
10.05-10.99
52 wk Range
1.06-10.99
Volume
14.27M
Average Volume (3m)
10.68M
1-Year Change
732%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
2142 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
12.18
Upside
+10.85%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Hbm Holdings Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Hbm Holdings Ltd Company Profile

HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor for treating myasthenia gravis; Porustobart HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4 for treating melanoma, colorectal cancer, hepatocellular carcinoma, and neuroendocrine neoplasm. It is also developing HBM7020 for treating hematologic carcinoma and autoimmune diseases; HBM9378 for the treatment of asthma and chronic obstructive pulmonary disease; and HBM1020, HBM1022, HBM9014, HBM7022, HBM7008, HBM9027, HBM7004, and HBM9033 for treating solid tumors. The company was incorporated in 2016 and is based in Suzhou, the People’s Republic of China.

Employees
183
Market
Hong Kong

Compare 2142 to Peers and Sector

Metrics to compare
2142
Peers
Sector
Relationship
P/E Ratio
393.9x−3.1x−0.5x
PEG Ratio
−4.290.040.00
Price/Book
8.8x3.8x2.6x
Price / LTM Sales
28.7x9.3x3.3x
Upside (Analyst Target)
17.1%245.6%43.3%
Fair Value Upside
Unlock−5.3%6.9%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 12.18
(+10.85% Upside)

Earnings

Latest Release
Apr 22, 2025
EPS / Forecast
-- / --
Revenue / Forecast
14.40M / --
EPS Revisions
Last 90 days

2142 Income Statement

FAQ

What Stock Exchange Does Hbm Trade On?

Hbm is listed and trades on the Hong Kong Stock Exchange stock exchange.

What Is the Stock Symbol for Hbm?

The stock symbol for Hbm is "2142."

What Is the Hbm Market Cap?

As of today, Hbm market cap is 8.25B.

What Is Hbm's Earnings Per Share (TTM)?

The Hbm EPS (TTM) is 0.00.

From a Technical Analysis Perspective, Is 2142 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Hbm Stock Split?

Hbm has split 0 times.

How Many Employees Does Hbm Have?

Hbm has 183 employees.

What is the current trading status of Hbm (2142)?

As of 11 Aug 2025, Hbm (2142) is trading at a price of 10.99, with a previous close of 10.40. The stock has fluctuated within a day range of 10.05 to 10.99, while its 52-week range spans from 1.06 to 10.99.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.